Skip to Content
Merck
  • AmotL2 disrupts apical-basal cell polarity and promotes tumour invasion.

AmotL2 disrupts apical-basal cell polarity and promotes tumour invasion.

Nature communications (2014-08-02)
Mahdi Mojallal, Yujuan Zheng, Sara Hultin, Stéphane Audebert, Tanja van Harn, Per Johnsson, Claes Lenander, Nicolas Fritz, Christin Mieth, Martin Corcoran, Frédérique Lembo, Marja Hallström, Johan Hartman, Nathalie M Mazure, Thomas Weide, Dan Grandér, Jean-Paul Borg, Per Uhlén, Lars Holmgren
ABSTRACT

The establishment and maintenance of apical-basal cell polarity is essential for the functionality of glandular epithelia. Cell polarity is often lost in advanced tumours correlating with acquisition of invasive and malignant properties. Despite extensive knowledge regarding the formation and maintenance of polarity, the mechanisms that deregulate polarity in metastasizing cells remain to be fully characterized. Here we show that AmotL2 expression correlates with loss of tissue architecture in tumours from human breast and colon cancer patients. We further show that hypoxic stress results in activation of c-Fos-dependent expression of AmotL2 leading to loss of polarity. c-Fos/hypoxia-induced p60 AmotL2 interacts with the Crb3 and Par3 polarity complexes retaining them in large vesicles and preventing them from reaching the apical membrane. The resulting loss of polarity potentiates the response to invasive cues in vitro and in vivo in mice. These data provide a molecular mechanism how hypoxic stress deregulates cell polarity during tumour progression.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Chromatin Immunoprecipitation (ChIP) Assay Kit, Contains all necessary reagents to perform 22 individual chromatin immunoprecipitation (ChIP) reactions using inexpensive protein A agarose beads.
Sigma-Aldrich
Phenol Red, powder, BioReagent, suitable for cell culture
Sigma-Aldrich
Phenol Red, ACS reagent
Sigma-Aldrich
N-[Tris(hydroxymethyl)methyl]acrylamide, contains ≤7% KCl, 93%
Sigma-Aldrich
MISSION® esiRNA, targeting mouse Ppfibp1